On December 23, 2025, a press release from Spiber, a biotech startup based in the small coastal city of Tsuruoka, Yamagata Prefecture, sent shockwaves through Japan. The company announced a business support agreement with Maya Kawana, CEO of brand consulting firm BOLD. Buried in her official bio was a bombshell: "Born as the eldest daughter of Masayoshi Son."

For 44 years, Kawana had never publicly acknowledged her relationship with the billionaire founder of SoftBank Group. So why now?

Kawana said revealing her identity was meant to signal a long-term commitment: she was not interested in a quick IPO or resale. Her goal, she said, was to build Spiber into a world-leading biotech company over the long haul. Financial observers noted a more pragmatic dimension. Spiber was facing roughly ¥36 billion (about $230 million) in financial debt due at the end of 2025, and the implicit backing of Japan's wealthiest family gave creditors some confidence the money would not simply vanish.

From Spider Silk Dreams to Brewed Protein Reality

Spiber was founded in 2007 by Kazuhide Sekiyama while he was a graduate student at Keio University's Institute for Advanced Biosciences in Tsuruoka. The founding vision was audacious: artificially mass-produce spider silk, a material that combines the tensile strength of steel with remarkable elasticity.

In 2013, Spiber achieved a world first, establishing the fundamental technology for mass-producing synthetic spider silk fibers. The company then evolved beyond spider silk, developing "Brewed Protein," a structural protein material produced through microbial fermentation. Unlike petroleum-based synthetics like polyester and nylon, Brewed Protein is plant-derived, biodegradable, and versatile enough for use in textiles, cosmetics, and industrial applications.

The technology attracted global attention. Burberry and Stella McCartney incorporated Brewed Protein into their products, and Japanese outdoor brand Goldwin (parent of The North Face Japan) became a close strategic partner. The government-backed Cool Japan Fund put in ¥14 billion (about $90 million) across 2018 and 2021, its single largest investment, and U.S. private equity firm Carlyle invested ¥10 billion (about $65 million) in 2021. In total, Spiber raised more than ¥100 billion (about $650 million) through funding rounds and debt instruments, reaching a peak valuation of ¥133 billion.

When Revenue Could Not Keep Up with Vision

Despite the technological achievements, Spiber's business fundamentals were catastrophic. The critical problem was scaling, translating laboratory breakthroughs into cost-competitive industrial production.

Spiber built a "mother plant" in Thailand and planned a massive factory in the United States, investing roughly $2.5 billion in the U.S. facility alone. Then reality intervened. COVID-19 delayed construction, the weakening yen sent raw material costs soaring, and the fundamental economics of bio-fermentation proved far more challenging than projected.

The numbers were brutal. In the year to December 2024, Spiber generated just ¥410 million (about $2.6 million) in revenue against a net loss of ¥29.5 billion. The year to December 2025 was worse: ¥177 million (about $1.1 million) in revenue, a net loss of ¥43.8 billion, and negative net assets of ¥28.1 billion, deep insolvency by any measure. Around ¥36 billion in financial debt was due by the end of 2025, part of it raised through a business-value securitization arranged by Mitsubishi UFJ Morgan Stanley with major banks and institutional investors participating.

An industry observer put the challenge in stark terms: "From one liter of petroleum, you can produce over 500 grams of synthetic fiber. With Spiber's process, you get about 50 grams. The cost math was never going to work at scale."

Private Restructuring and the Birth of CRANE

Unable to repay its debts, Spiber entered a "private restructuring" process (shiteki seiri), a Japanese out-of-court debt workout procedure where creditors negotiate directly without going through bankruptcy courts. This was a first for a Japanese unicorn.

On March 25, 2026, Spiber's shareholders approved the restructuring and business transfer to CRANE Inc., a new company Kawana established on February 25, 2026, in Tsuruoka. The transfer price was roughly ¥5 billion (about $31 million), a fraction of Spiber's peak valuation of ¥133 billion (about $860 million).

CRANE inherited Spiber's technology, intellectual property, personnel, and equipment, while the debt stayed with the old entity. The original Spiber will be renamed "Structural Protein Business Asset Management" and undergo special liquidation in about two years, after its U.S. subsidiary is wound down. Creditor banks reportedly agreed to write off their claims.

On April 1, 2026, the new Spiber launched. Maya Kawana assumed the role of CEO and Representative Director. Founders Sekiyama and co-founder Jun'ichi Sugawara stepped down from management, becoming "Chief Research Fellows" focused on solving technical challenges and optimizing the product development pipeline.

Who Is Maya Kawana? Goldman Sachs, BOLD, and a Deliberate Distance from SoftBank

Born in April 1981, Kawana attended Keio from elementary school through university, graduating from the Faculty of Economics in 2004. She joined Goldman Sachs Japan's investment banking division, working on corporate financing and M&A advisory.

After Goldman Sachs, she served as a program presenter at Business Breakthrough, a business education company founded by legendary management consultant Kenichi Ohmae. She later became General Manager at Afiniti Japan, an AI-driven customer matching company, before founding her own brand consulting firm BOLD in 2019. She has also served as an outside director at Ai Robotics, a company listed on the Tokyo Stock Exchange Growth Market.

Notably, Kawana has never held any position at SoftBank Group. Her father has repeatedly said SoftBank is not a family business and that future leadership will be determined by merit, not bloodline. That separation is part of why her Spiber involvement matters: it is presented as her own business decision, not a SoftBank Group investment.

The New Spiber: Lean Team, Global Ambitions

The new company's executive lineup reflects an intentionally international composition. Daniel Meyer serves as Chief Strategy and Finance Officer, Li Jiang leads R&D, and former Spiber executives handle operations and business development. Twelve strategic partners have signed on, including Goldwin, Aderans (Japan's largest wig manufacturer), Komatsu Matere (textile manufacturer), and Shimaseiki (knitting machine maker).

The U.S. operations, once the centerpiece of Spiber's growth plans, are being liquidated. The new Spiber will focus on Japan and Thailand as its operational base, pursuing a leaner, more commercially focused strategy.

Kawana's stated mission: "I will ensure that this flame of hope born in Tsuruoka is never extinguished, and will guide Spiber, this vessel of great potential, to a form the world can be proud of."

Spiber in the Global Biomaterials Race

Spiber isn't the only company trying to crack synthetic protein fibers. The global biomaterials landscape includes U.S.-based Bolt Threads (approximately $41 million in 2024 revenue), which produces Microsilk and mushroom-based leather alternative Mylo, and Germany's AMSilk ($30 million revenue), which focuses on biomedical coatings and industrial applications. Israel's Seevix specializes in self-healing spider silk for surgical applications, while U.S.-based Kraig Biocraft Laboratories is developing transgenic silkworms that produce spider silk proteins.

North America accounts for roughly 38% of the global synthetic spider silk market, which is growing at an annual rate of about 15%. Applications extend well beyond fashion: medical sutures, tissue scaffolding, drug delivery systems, lightweight armor, and aerospace structural components.

What distinguishes Spiber's Brewed Protein technology is its versatility, it can produce a wide range of structural proteins through microbial fermentation, not just spider silk analogs. The fundamental challenge remains the same across the industry: bringing production costs down to compete with dirt-cheap petroleum-based synthetics.

Japan's Deep-Tech Dilemma: Brilliant Technology, Broken Business Models

Spiber's rise and fall encapsulates a structural challenge facing Japan's startup ecosystem. The government's 2022 "Five-Year Startup Development Plan" set a target of 100 unicorns by 2027, with ¥10 trillion in total startup investment. As of now, Japan has roughly 20 unicorns, far behind the U.S. (around 700) and China (around 170).

Deep-tech companies in materials science and hardware face particularly steep odds. R&D timelines are long, capital requirements are enormous, and the path to revenue is uncertain, a poor fit for venture funds that expect returns within five to seven years.

Spiber is the case in point. World-class technology consumed more than ¥100 billion before generating meaningful revenue. It needed "patient capital," money willing to wait 15 to 20 years, but was funded through structures built for much shorter timescales. The Cool Japan Fund, which lost its single largest investment here, has seen its accumulated losses widen to the point that the government is weighing whether to shut it down.

Could Kawana's model of "family capital with long-term commitment" offer an alternative? Just as Masayoshi Son's early bet on Alibaba took over a decade to pay off, some argue Japan's deep-tech sector needs similarly patient backers who will not demand quick exits. Whether Kawana can prove that with Spiber is still an open question.

In Japan, the debate continues over family business succession, startup accountability, and the gap between the country's technological capabilities and its ability to commercialize them. How does your country handle startup failures and turnarounds? Is government support for biotech effective where you live? We would like to hear your perspective and examples from your country.

References